Effects of Azathioprine and Mycophenolate Mofetil-Immunosuppressive Regimens on the Erythropoietic System of Renal Transplant Recipients

H. T. Khosroshahi, A. Asghari, R. Estakhr, B. Baiaz, M. R. Ardalan, Mohammadali Mohajel Shoja

Research output: Contribution to journalArticle

23 Citations (Scopus)

Abstract

Introduction: Azathioprine (AZA) and mycophenolate mofetil (MMF) are major immunosupressants used to prevent rejection following renal transplantation. Bone marrow suppression is a potential adverse effect of these agents manifesting itself as leukopenia, thrombocytopenia, and anemia. The aim of this study was to compare the effects of AZA versus MMF immunosuppressive regimens on the erythropoietic system of renal transplant recipients within 6 months after transplantation. Methods: Eighty kidney allograft recipients who were on AZA (n = 40) or MMF (n = 40) plus cyclosporine and prednisolone were enrolled in this study. Hematologic parameters included red blood cell counts, hemoglobin (Hb), hematocrit, mean corpuscular volume, mean corpuscular hemoglobin (MCH) and mean corpuscular hemoglobin concentration (MCHC) and were measured before and at 1 week, as well as 1 and 6 months posttransplantation. Plasma erythropoietin level was measured at the end of 6 months. Statistical analysis was performed with Student t test; a P value less than .05 was considered significant. Results: There was no significant difference between the two groups regarding red blood cell counts. High Hb level was noted at 1 and 6 months posttransplantation among patients who received MMF. MCH and MCHC were higher among patients on MMF compared with those on AZA at 1 week and 1 month posttransplant. Although the mean plasma erythropoietin levels in AZA-treated patients were higher than those of MMF-treated patients, the trend did not reach statistical significance (P = .066). Conclusion: MMF administration was apparently associated with a higher level of hemoglobin compared with AZA among renal allograft recipients with good graft function at 6 months posttransplantation.

Original languageEnglish (US)
Pages (from-to)2077-2079
Number of pages3
JournalTransplantation Proceedings
Volume38
Issue number7
DOIs
StatePublished - Sep 1 2006
Externally publishedYes

Fingerprint

Mycophenolic Acid
Azathioprine
Immunosuppressive Agents
Erythrocyte Indices
Kidney
Hemoglobins
Erythrocyte Count
Erythropoietin
Allografts
Leukopenia
Prednisolone
Transplant Recipients
Hematocrit
Thrombocytopenia
Kidney Transplantation
Cyclosporine
Anemia
Transplantation
Bone Marrow
Students

ASJC Scopus subject areas

  • Surgery
  • Transplantation

Cite this

Effects of Azathioprine and Mycophenolate Mofetil-Immunosuppressive Regimens on the Erythropoietic System of Renal Transplant Recipients. / Khosroshahi, H. T.; Asghari, A.; Estakhr, R.; Baiaz, B.; Ardalan, M. R.; Mohajel Shoja, Mohammadali.

In: Transplantation Proceedings, Vol. 38, No. 7, 01.09.2006, p. 2077-2079.

Research output: Contribution to journalArticle

Khosroshahi, H. T. ; Asghari, A. ; Estakhr, R. ; Baiaz, B. ; Ardalan, M. R. ; Mohajel Shoja, Mohammadali. / Effects of Azathioprine and Mycophenolate Mofetil-Immunosuppressive Regimens on the Erythropoietic System of Renal Transplant Recipients. In: Transplantation Proceedings. 2006 ; Vol. 38, No. 7. pp. 2077-2079.
@article{e5bc17fccb864f54b053c4f9be89172c,
title = "Effects of Azathioprine and Mycophenolate Mofetil-Immunosuppressive Regimens on the Erythropoietic System of Renal Transplant Recipients",
abstract = "Introduction: Azathioprine (AZA) and mycophenolate mofetil (MMF) are major immunosupressants used to prevent rejection following renal transplantation. Bone marrow suppression is a potential adverse effect of these agents manifesting itself as leukopenia, thrombocytopenia, and anemia. The aim of this study was to compare the effects of AZA versus MMF immunosuppressive regimens on the erythropoietic system of renal transplant recipients within 6 months after transplantation. Methods: Eighty kidney allograft recipients who were on AZA (n = 40) or MMF (n = 40) plus cyclosporine and prednisolone were enrolled in this study. Hematologic parameters included red blood cell counts, hemoglobin (Hb), hematocrit, mean corpuscular volume, mean corpuscular hemoglobin (MCH) and mean corpuscular hemoglobin concentration (MCHC) and were measured before and at 1 week, as well as 1 and 6 months posttransplantation. Plasma erythropoietin level was measured at the end of 6 months. Statistical analysis was performed with Student t test; a P value less than .05 was considered significant. Results: There was no significant difference between the two groups regarding red blood cell counts. High Hb level was noted at 1 and 6 months posttransplantation among patients who received MMF. MCH and MCHC were higher among patients on MMF compared with those on AZA at 1 week and 1 month posttransplant. Although the mean plasma erythropoietin levels in AZA-treated patients were higher than those of MMF-treated patients, the trend did not reach statistical significance (P = .066). Conclusion: MMF administration was apparently associated with a higher level of hemoglobin compared with AZA among renal allograft recipients with good graft function at 6 months posttransplantation.",
author = "Khosroshahi, {H. T.} and A. Asghari and R. Estakhr and B. Baiaz and Ardalan, {M. R.} and {Mohajel Shoja}, Mohammadali",
year = "2006",
month = "9",
day = "1",
doi = "10.1016/j.transproceed.2006.06.043",
language = "English (US)",
volume = "38",
pages = "2077--2079",
journal = "Transplantation Proceedings",
issn = "0041-1345",
publisher = "Elsevier USA",
number = "7",

}

TY - JOUR

T1 - Effects of Azathioprine and Mycophenolate Mofetil-Immunosuppressive Regimens on the Erythropoietic System of Renal Transplant Recipients

AU - Khosroshahi, H. T.

AU - Asghari, A.

AU - Estakhr, R.

AU - Baiaz, B.

AU - Ardalan, M. R.

AU - Mohajel Shoja, Mohammadali

PY - 2006/9/1

Y1 - 2006/9/1

N2 - Introduction: Azathioprine (AZA) and mycophenolate mofetil (MMF) are major immunosupressants used to prevent rejection following renal transplantation. Bone marrow suppression is a potential adverse effect of these agents manifesting itself as leukopenia, thrombocytopenia, and anemia. The aim of this study was to compare the effects of AZA versus MMF immunosuppressive regimens on the erythropoietic system of renal transplant recipients within 6 months after transplantation. Methods: Eighty kidney allograft recipients who were on AZA (n = 40) or MMF (n = 40) plus cyclosporine and prednisolone were enrolled in this study. Hematologic parameters included red blood cell counts, hemoglobin (Hb), hematocrit, mean corpuscular volume, mean corpuscular hemoglobin (MCH) and mean corpuscular hemoglobin concentration (MCHC) and were measured before and at 1 week, as well as 1 and 6 months posttransplantation. Plasma erythropoietin level was measured at the end of 6 months. Statistical analysis was performed with Student t test; a P value less than .05 was considered significant. Results: There was no significant difference between the two groups regarding red blood cell counts. High Hb level was noted at 1 and 6 months posttransplantation among patients who received MMF. MCH and MCHC were higher among patients on MMF compared with those on AZA at 1 week and 1 month posttransplant. Although the mean plasma erythropoietin levels in AZA-treated patients were higher than those of MMF-treated patients, the trend did not reach statistical significance (P = .066). Conclusion: MMF administration was apparently associated with a higher level of hemoglobin compared with AZA among renal allograft recipients with good graft function at 6 months posttransplantation.

AB - Introduction: Azathioprine (AZA) and mycophenolate mofetil (MMF) are major immunosupressants used to prevent rejection following renal transplantation. Bone marrow suppression is a potential adverse effect of these agents manifesting itself as leukopenia, thrombocytopenia, and anemia. The aim of this study was to compare the effects of AZA versus MMF immunosuppressive regimens on the erythropoietic system of renal transplant recipients within 6 months after transplantation. Methods: Eighty kidney allograft recipients who were on AZA (n = 40) or MMF (n = 40) plus cyclosporine and prednisolone were enrolled in this study. Hematologic parameters included red blood cell counts, hemoglobin (Hb), hematocrit, mean corpuscular volume, mean corpuscular hemoglobin (MCH) and mean corpuscular hemoglobin concentration (MCHC) and were measured before and at 1 week, as well as 1 and 6 months posttransplantation. Plasma erythropoietin level was measured at the end of 6 months. Statistical analysis was performed with Student t test; a P value less than .05 was considered significant. Results: There was no significant difference between the two groups regarding red blood cell counts. High Hb level was noted at 1 and 6 months posttransplantation among patients who received MMF. MCH and MCHC were higher among patients on MMF compared with those on AZA at 1 week and 1 month posttransplant. Although the mean plasma erythropoietin levels in AZA-treated patients were higher than those of MMF-treated patients, the trend did not reach statistical significance (P = .066). Conclusion: MMF administration was apparently associated with a higher level of hemoglobin compared with AZA among renal allograft recipients with good graft function at 6 months posttransplantation.

UR - http://www.scopus.com/inward/record.url?scp=33846098257&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33846098257&partnerID=8YFLogxK

U2 - 10.1016/j.transproceed.2006.06.043

DO - 10.1016/j.transproceed.2006.06.043

M3 - Article

VL - 38

SP - 2077

EP - 2079

JO - Transplantation Proceedings

JF - Transplantation Proceedings

SN - 0041-1345

IS - 7

ER -